← Back to headlines
Omeros Shares Rise as AstraZeneca's Ultomiris Fails in Blood Disorder Trial
Omeros' stock saw gains following news that AstraZeneca's drug Ultomiris failed to meet its primary endpoint in a clinical trial for a rare blood disorder.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
